GlassScriptPhysician profile
Arthur E Jimenez
NPI 1578532131
$4,759.70
in general payments reported to CMS, 2019-2025
28 companies · $576 in 2025
The $576 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $944 · 2020: $311 · 2021: $931 · 2022: $948 · 2023: $582 · 2024: $468 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,567 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,567.35 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $811.83 | 2019-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $638.61 | 2019-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $464.19 | 2021-2022 | |
| Amgen INC. | $378.10 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.22 | 2019-2025 | Jardiance |
| Abbott Laboratories | $287.23 | 2021-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $284.23 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $260.00 | 2022-2025 | Dupixent |
| Horizon Therapeutics Plc | $211.86 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $195.73 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Lifescan, INC. | $110.55 | 2020-2022 | |
| Sanofi Pasteur INC. | $94.00 | 2019 | |
| Mannkind Corporation | $80.52 | 2023 | Afrezza |
| Abbvie INC. | $76.17 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $71.45 | 2021-2023 | Gardasil 9, M-M-R II, Proquad |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $70.18 | 2023-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.29 | 2024-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $54.04 | 2019-2022 | |
| Exact Sciences Corporation | $47.69 | 2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $40.49 | 2025 | Zoryve |
| Sunovion Pharmaceuticals INC. | $40.42 | 2019 | |
| Paratek Pharmaceuticals, INC. | $30.88 | 2025 | Xhance |
| Shield Therapeutics INC | $22.48 | 2025 | |
| Hologic Sales and Service, LLC | $19.39 | 2024 | Thinprep 2000 Processor |
| Scilex Pharmaceuticals INC. | $18.38 | 2023 | Ztlido |
| Optinose US, INC. | $18.05 | 2025 | |
| Pfizer INC. | $16.71 | 2019 | |
| Redhill Biopharma INC. | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.